COVID-19 mortality in patients on anticoagulants and antiplatelet agents

Br J Haematol. 2020 Aug;190(4):e192-e195. doi: 10.1111/bjh.16968. Epub 2020 Jul 19.

Abstract

Coagulopathy (Tang, et al 2020) and a prothrombotic diathesis with high D‐dimer and fibrinogen levels (Al‐Samkari, et al 2020) are associated with coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Extensive thrombosis in small vessels and the microvasculature in lungs and extrapulmonary organs has been confirmed histologically (Zhang et al 2020). Early studies showed that the venous thromboembolism (VTE) incidence in hospitalised COVID‐19 patients can be as high as 25% (Songping, et al 2020), and more recent studies have indicated this can be expanded to other macrovascular thrombotic complications, such as a higher than expected prevalence of pulmonary emboli in patients with COVID‐19 (Klok, et al 2020, Stoneham, et al).

Keywords: COVID-19; anticoagulants; antiplatelets; mortality; thrombosis; thrombosis (venous).

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage*
  • COVID-19 / blood
  • COVID-19 / drug therapy*
  • COVID-19 / mortality*
  • Disease-Free Survival
  • Female
  • Hospital Mortality*
  • Humans
  • Male
  • Platelet Aggregation Inhibitors / administration & dosage*
  • SARS-CoV-2*
  • Survival Rate

Substances

  • Anticoagulants
  • Platelet Aggregation Inhibitors